mercredi 24 octobre 2018

Onco Actu du 24 octobre 2018

1. Biologie

World-first study uncovers potential DNA secrets of prostate cancer in African Men [Garvan Institute]

2. Etiologie

Tall people at greater risk of cancer 'because they have more cells' [The Guardian]

2.6 Etiologie - Environnement

Monsanto trial: judge rejects bid to overturn landmark cancer verdict [The Guardian]

Judge upholds Monsanto weed killer cancer verdict but slashes damages to groundsman [The Telegraph]

3.1 Prévention - Tabac

‘If Philip Morris really wants people to stop smoking they should stop making cigarettes’ [Cancer Research UK]

3.1.1 Prévention - Tabac - e-cigs

Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s ongoing commitment to improving efficiency, transparency of tobacco product application review process as part of FDA’s comprehensive framework to reduce tobacco-related disease and death [FDA]

JUUL's social media campaign resonates alarmingly with teens [Reuters]

3.8 Prévention - Alimentation

Eating organic food linked with lower cancer risk [NHS Choices]

No, Organic Food Doesn't Reduce Cancer Risk. That's Biologically Impossible [ACSH]

Organic foods tied to slightly lower cancer risk [Reuters]

Organic Foods for Cancer Prevention—Worth the Investment? [JAMA Internal Medicine]

4. Dépistage, diagnostic et pronostic

Study Improves the Quality of Biopsy Specimens for Cancer Research [NCI]

4.12 Biopsies liquides

HPV blood test shows promise for tracking head and neck cancer after treatment [UNC]

4.7 Dép., diag. & prono. - Col de l'utérus

Cervical screening: Millions missing smear tests [BBC News]

5.12.1 Immunothérapies - partenariats

AstraZeneca strikes big, multipart immuno-oncology deal with Innate [FierceBiotech]

AstraZeneca strengthens and expands oncology development and commercialisation collaboration with Innate Pharma [AstraZeneca]

AstraZeneca is paying Innate Pharma at least $242M in near-term cash to sew up rights to monalizumab-plus [EndPoints]

AstraZeneca digs deeper into cancer with Innate stake [Reuters]

5.12.3 Immunothérapies-combinaisons

Bristol-Myers' Opdivo-Yervoy combo hits a regulatory snag in lung cancer [FiercePharma]

Bristol-Myers Squibb Provides Update on the Ongoing Regulatory Review of Opdivo Plus Low-Dose Yervoy in First-Line Lung Cancer Patients with Tumor Mutational Burden ≥10 mut/Mb [BMS]

5.12.5 Immunothérapies - Pharma

Amid pipeline woes, Celgene brings on Keytruda and Bavencio R&D executive in shake-up [FierceBiotech]

5.12.6 Immunothérapies - AMM

Immunotherapy Drug Cemiplimab Approved for Advanced Squamous Cell Skin Cancer [NCI]

5.2 Pharma

Phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer meets primary endpoint [Bayer]

Bayer, Orion drug shown to delay spread of prostate cancer [Reuters]

Genmab Announces Positive Topline Results in Phase III CASSIOPEIA Study of Daratumumab in Front Line Multiple Myeloma [Genmab]

Merrimack Pharma’s stock plunges (again) on its latest cancer drug trial flop [EndPoints]

Real-world study shows using Giotrif®/Gilotrif® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC [Boehringer Ingelheim]

5.2.3 Pharma - économie

A New Targeted Cancer Company To Watch [Forbes]

5.3 Traitements - FDA, EMA, NICE...

It’s All in the Numbers: FDA Issues New Draft Guidance on Presenting Quantitative Efficacy and Risk Information in DTC Promotion [FDA Law Blog]

5.3.4 Traitements - AMM (FDA, EMA,...)

Summary of opinion (post authorisation) - Keytruda pembrolizumab (EMA]

5.4 Traitements - Economie

NICE spurns Lilly’s breast cancer drug Verzenio in favor of rivals from Pfizer and Novartis [FiercePharma]

NICE rejects Elil Lilly's Verzenio for breast cancer in draft guidance [Pharmafile]

5.6 ESMO

ESMO's not what it used to be—and that's a good thing, executives say [FiercePharma]

ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front [Xconomy] ESMO - Sein (triple négatif)

Immunotherapy trial shows promise for some women with an aggressive breast cancer [Cancer Research UK] ESMO - Sein (palbociclib)

Targeted drug could extend lives of some women with advanced breast cancer [Cancer Research UK]

6.1 Observation

Bowel cancer on the rise among young people in Europe [The Guardian]

6.10 Politiques

Europe’s Nobel laureates step up warnings about Brexit’s effect on science [Nature]

6.12 Ethique

Cancer Research to cut funding for scientists who bully colleagues [The Guardian]

6.13 Soins palliatifs

2018 Palliative and Supportive Care in Oncology Symposium Press Program to Feature New Research on Pain Management and Immunotherapy-Related Toxicities [ASCO]

6.5 Médecines alternatives/complémentaires

Crowdfunding raises millions for unproven — and potentially harmful — treatments [STAT]

6.7.1 IA/bioinformatique

Head of IBM Watson Health leaving post after company stumbles, growing criticism [STAT]